- Home
- ARTW vs KZIA Comparison
ARTW vs KZIA Comparison
Compare ARTW & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ARTW | KZIA |
|---|---|---|
| Founded | 1956 | 1994 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.9M | 161.5M |
| IPO Year | N/A | 1999 |
Fundamental Metrics
Financial Performance| Metric | ARTW | KZIA |
|---|---|---|
| Price | $2.30 | $6.50 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $17.67 |
| AVG Volume (30 Days) | 24.6K | ★ 245.6K |
| Earning Date | 02-10-2026 | 12-26-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.49 | N/A |
| Revenue | ★ $24,079,949.00 | $1,199,108.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $5.89 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.43 | $2.86 |
| 52 Week High | $4.71 | $17.40 |
Technical Indicators
Market Signals| Indicator | ARTW | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 49.90 | 40.47 |
| Support Level | $2.29 | $5.44 |
| Resistance Level | $2.41 | $6.96 |
| Average True Range (ATR) | 0.10 | 1.44 |
| MACD | 0.01 | -0.51 |
| Stochastic Oscillator | 50.00 | 16.09 |
Price Performance
Historical ComparisonAbout ARTW Art's-Way Manufacturing Co. Inc.
Art's-Way Manufacturing Co Inc is a manufacturer of agricultural equipment. It has two reportable segments: Agricultural Products, and Modular Buildings. The Agricultural Products segment fabricates and sells farming products as well as related equipment and replacement parts for these products in the United States and world wide. Its Modular Buildings segment manufactures and installs modular buildings for animal containment and various laboratory uses. It derives revenues from the Agricultural Products segment.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.